National Institutes of Health: Melanoma trials
The registry lists 220 Melanoma studies with National Institutes of Health as lead sponsor. 14 are open to participants now and 92 have results posted.
Early Phase 1 1Phase 1 66Phase 2 147Phase 3 10No phase 18(a study in two phases counts in both)
Studies
Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory LymphomasCompletedNCT00019019Phase 1
- Thalidomide and SU5416 in Treating Patients With Metastatic MelanomaCompletedNCT00017316Phase 2
- Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant MelanomaCompletedNCT00006243Not applicable
- Thalidomide and Dacarbazine for Metastatic MelanomaStatus unknownNCT00006200Phase 2
- SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously TreatedTerminatedNCT00006003Phase 2
- O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic MelanomaCompletedNCT00005961Phase 2
- Vaccine Plus Interleukin-2 in Treating Patients With Advanced MelanomaCompletedNCT00005949Phase 2
- Gene Therapy and Ganciclovir in Treating Patients With Stage IV MelanomaCompletedNCT00005057Phase 1
- Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant MelanomaCompletedNCT00004244Phase 1
- Vaccine Therapy in Treating Patients With Unresectable Metastatic MelanomaCompletedNCT00004148Phase 1
- Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or LegCompletedNCT00003789Phase 3
- Vaccine Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00003665Phase 1
- Vaccine Therapy in Treating Patients With MelanomaCompletedNCT00003556Phase 1
- Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic MelanomaTerminatedNCT00003552Phase 1/2
- Microarray Analysis for Human Genetic DiseaseCompletedNCT00001898
- Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal SequenceCompletedNCT00001705Phase 2
- Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and TyrosinaseCompletedNCT00001685Phase 2
- Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the ExtremityCompletedNCT00001577Phase 1
- A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's AdjuvantCompletedNCT00001439Phase 1
- A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity MelanomaCompletedNCT00001296Phase 3